entertainment -WSS

entertainment

author：focus 2025-09-27 19:50:03 - browse：3

Thomas Massie -- health policy coverage from STAT — Rep. Thomas Massie (R-Ky.) Kevin Dietsch/Getty Images

WASHINGTON — House lawmakers late Tuesday voted to attach a U.S. ban on controversial infectious disease research to legislation that could ultimately fund federal health agencies like the National Institutes of Health.

The bill would bar any federal agencies from funding so-called gain-of-function research, which involves altering a pathogen to study its spread, potentially making it more transmissible or severe in the process.

The spending bill already included a restriction on funding this research in any country determined to be a “foreign adversary,” including China. Scientists at the Wuhan Institute of Virology studied gain-of-function in some viruses, fueling theories that the Covid-19 pathogen was a lab leak. Those theories have never definitively been proven.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： There’s no way to know how good AI health technologies are

Wikipedia

WSS

340B reform proposal comes out of Senate working group

Researchers CRISPR chickens in bid to protect them from bird flu

Readout LOUD: Venture capital, Gilead, and more M&A

Akero's treatment for NASH falls short in cirrhosis study

A revolution in caring for preterm infants

Akero's treatment for NASH falls short in cirrhosis study

knowledge

entertainment

Wikipedia

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Nick Jonas talks about managing diabetes along with his career

Tori Bowie and the unacceptable rates of Black maternal death

Cano Health’s bankruptcy is a warning for Medicare Advantage

Psychedelics group wrestles with new pharma identity

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Medical leaders decry Supreme Court decision on affirmative action

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

Hollywood unions extend contract negotiations for actors

Why Novartis is going to walk from its acquisition of MorphoSys

hotspot

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

A fraught question for the kids of Alzheimer’s: Is it coming for us?

Peter Marks talks Operation Warp Speed for Rare Diseases

Readout LOUD: Venture capital, Gilead, and more M&A

The Biogen Aduhelm mess could happen again

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

knowledge

Wikipedia

focus

focus